Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.

Abstract excerpt

Over the last decade, major advances have been made in the elucidation of mechanisms involved in leukemogenesis, and this is particularly true with regard to deregulated protein tyrosine kinase (PTK) activation. This progress had led to the development of small molecules that specifically inhibit the abnormally activated kinase. The first example of such targeted therapy is imatinib-mesylate, an inhibitor of the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to fms-Like Tyrosine Kinase 3
• Share to Gene Expression Regulation, Enzymologic